These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26351210)

  • 1. Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells.
    Xu B; Tao ZZ
    Oncol Res; 2014; 22(4):213-217. PubMed ID: 26351210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
    Wang Z; Wang Q; He T; Li W; Liu Y; Fan Y; Wang Y; Wang Q; Chen J
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1083-1091. PubMed ID: 32072678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
    Kim MK; Jeon YK; Woo JK; Choi Y; Choi DH; Kim YH; Kim CW
    Mol Cancer; 2011 Aug; 10():98. PubMed ID: 21843371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
    Hatami E; Nagesh PKB; Jaggi M; Chauhan SC; Yallapu MM
    Eur J Pharmacol; 2020 Dec; 888():173486. PubMed ID: 32805254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment.
    Vandana M; Sahoo SK
    Eur J Pharm Biopharm; 2015 Aug; 94():83-93. PubMed ID: 25968494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
    Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
    Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
    Meiler J; Guyot M; Hoffarth S; Wesarg E; Höhn Y; Breitenbuecher F; Schuler M
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1385-94. PubMed ID: 22488173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
    Siena L; Pace E; Ferraro M; Di Sano C; Melis M; Profita M; Spatafora M; Gjomarkaj M
    Immunology; 2014 Feb; 141(2):242-55. PubMed ID: 24128051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of atorvastatin and metformin denotes their individual and combined antiproliferative effects in non-small cell lung cancer.
    Salim EI; Elsebakhy S; Hessien M
    Fundam Clin Pharmacol; 2024 Jun; 38(3):550-560. PubMed ID: 38258539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
    Pasqualetti G; Ricciardi S; Mey V; Del Tacca M; Danesi R
    Lung Cancer; 2011 Nov; 74(2):197-205. PubMed ID: 21529991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
    Zhang L; Qi Y; Xing K; Qian S; Zhang P; Wu X
    Oncol Rep; 2018 Aug; 40(2):1046-1054. PubMed ID: 29917169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
    Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
    PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
    Wang X; Chen F; Gou S
    Bioorg Chem; 2020 Nov; 104():104234. PubMed ID: 32920359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
    Sei S; Mussio JK; Yang QE; Nagashima K; Parchment RE; Coffey MC; Shoemaker RH; Tomaszewski JE
    Mol Cancer; 2009 Jul; 8():47. PubMed ID: 19594950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.